Advertisement

Angioimmunoblastic T-Cell Lymphoma

  • Mariko Yabe
  • Ahmet Dogan
  • Steven M. Horwitz
  • Alison J. MoskowitzEmail author
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 176)

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common types of T-cell lymphoma, representing about 15–20% of cases of peripheral T-cell lymphoma (PTCL). It is characterized by a unique clinical presentation and distinct pathologic and molecular features. Classes of drugs particularly active in AITL are emerging; however, treatment of relapsed and refractory disease remains a challenge. This chapter reviews the epidemiology, clinical presentation, pathogenesis, diagnosis, and treatment of AITL.

Keywords

Angioimmunoblastic T-cell lymphoma Follicular helper T-cell Pathology Treatment 

References

  1. 1.
    Frizzera G, Moran EM, Rappaport H (1974) Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1:1070–1073PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Lukes RJ, Tindle BH (1975) Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin’s disease. New Engl J Med 292:1–8PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Lennert K (1979) Nature, prognosis and nomenclature of angioimmunoblastic (lymphadenopathy (lymphogranulomatosis X or T-zone lymphoma). Deutsche medizinische Wochenschrift 104:1246–1247PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Feller AC, Griesser H, Schilling CV, Wacker HH, Dallenbach F, Bartels H, Kuse R, Mak TW, Lennert K (1988) Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol 133:549–556PubMedPubMedCentralGoogle Scholar
  5. 5.
    Kaneko Y, Maseki N, Sakurai M, Takayama S, Nanba K, Kikuchi M, Frizzera G (1988) Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive “angioimmunoblastic lymphadenopathy with dysproteinemia-type” features. Blood 72:413–421PubMedPubMedCentralGoogle Scholar
  6. 6.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the international Lymphoma study group. Blood 84:1361–1392PubMedPubMedCentralGoogle Scholar
  7. 7.
    Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J (2000) Lymphoma classification—from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 11(Suppl 1):3–10PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Vose J, Armitage J, Weisenburger D (2008) International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130Google Scholar
  9. 9.
    Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P (2008) Groupe d’Etude des Lymphomes de lA. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111:4463–4470PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Huh J (2009) Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol 131:640–646PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    de Leval L, Gisselbrecht C, Gaulard P (2010) Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 148:673–689PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Singh A, Schabath R, Ratei R, Stroux A, Klemke CD, Nebe T, Florcken A, van Lessen A, Anagnostopoulos I, Dorken B, Ludwig WD, Pezzutto A, Westermann J (2014) Peripheral blood sCD3(−) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 32:16–21PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Willenbrock K, Brauninger A, Hansmann ML (2007) Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 138:733–739PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, Lamant L, Leroy K, Briere J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952–4963CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A (2005) Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 106:1501–1502PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Forster R (2000) Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 192:1545–1552PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Cortes JR, Palomero T (2016) The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol 23:434–443PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Ueno H, Banchereau J, Vinuesa CG (2015) Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 16:142–152PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Vinuesa CG, Linterman MA, Yu D, MacLennan IC (2016) Follicular helper T cells. Annu Rev Immunol 34:335–368PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Leavenworth JW, Verbinnen B, Yin J, Huang H, Cantor H (2015) A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol 16:96–106PubMedCrossRefGoogle Scholar
  21. 21.
    Nurieva RI, Chung Y, Martinez GJ, Yang XO, Tanaka S, Matskevitch TD, Wang YH, Dong C (2009) Bcl6 mediates the development of T follicular helper cells. Science 325:1001–1005PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Couronne L, Bastard C, Bernard OA (2012) TET2 and DNMT3A mutations in human T-cell lymphoma. New Engl J Med 366:95–96PubMedCrossRefGoogle Scholar
  23. 23.
    Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM (2014) A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123:1293–1296PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S (2014) Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171–175PubMedCrossRefGoogle Scholar
  25. 25.
    Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166–170PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Jaffe AB, Hall A (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21:247–269PubMedCrossRefGoogle Scholar
  27. 27.
    Henning SW, Galandrini R, Hall A, Cantrell DA (1997) The GTPase Rho has a critical regulatory role in thymus development. EMBO J 16:2397–2407PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Pernis AB (2009) Rho GTPase-mediated pathways in mature CD4+ T cells. Autoimmun Rev 8:199–203PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, Kim J, Kim SJ, Kim WS, Lee S, Ko YH (2014) A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46:371–375PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, Kataoka TR, Hirata M, Aoki K, Nakano K, Kitanaka A, Sakata-Yanagimoto M, Egami S, Shiraishi Y, Chiba K, Tanaka H, Shiozawa Y, Yoshizato T, Suzuki H, Kon A, Yoshida K, Sato Y, Sato-Otsubo A, Sanada M, Munakata W, Nakamura H, Hama N, Miyano S, Nureki O, Shibata T, Haga H, Shimoda K, Katada T, Chiba S, Watanabe T, Ogawa S (2016) Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood 127:596–604PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127:2375–2390PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, Chan LC, Chan WC, Gaulard P, Mak TW (2012) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119:1901–1903PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839–843PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144–147PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC (2015) IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126:1741–1752PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, Enami T, Kamada Y, Kato T, Uchida K, Nanmoku T, Obara N, Suzukawa K, Sanada M, Nakamura N, Aburatani H, Ogawa S, Chiba S (2014) Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J 4:e264PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804–3815PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, Horst HA, Germing U, Dohner H, Dohner K (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol Official J Am Soc Clin Oncol 28:3636–3643CrossRefGoogle Scholar
  39. 39.
    Scourzic L, Couronne L, Pedersen MT, Della Valle V, Diop M, Mylonas E, Calvo J, Mouly E, Lopez CK, Martin N, Fontenay M, Bender A, Guibert S, Dubreuil P, Dessen P, Droin N, Pflumio F, Weber M, Gaulard P, Helin K, Mercher T, Bernard OA (2016) DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia 30:1388–1398PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, Hung S, Rosenwald A, Gascoyne R, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Xiao W, Borgstahl GE, Davis S, Steidl C, McKeithan T, Iqbal J, Chan WC (2016) Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 30:1062–1070PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais JP, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P, de Leval L (2016) Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128:1490–1502PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, Jang HY, Lee JE, Kim J, Kim SJ, Ko YH, Lee S (2016) Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica 101:757–763PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Palacios EH, Weiss A (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23:7990–8000PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Attygalle AD, Feldman AL, Dogan A (2013) ITK/SYK translocation in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 37:1456–1457PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Vaque JP, Gomez-Lopez G, Monsalvez V, Varela I, Martinez N, Perez C, Dominguez O, Grana O, Rodriguez-Peralto JL, Rodriguez-Pinilla SM, Gonzalez-Vela C, Rubio-Camarillo M, Martin-Sanchez E, Pisano DG, Papadavid E, Papadaki T, Requena L, Garcia-Marco JA, Mendez M, Provencio M, Hospital M, Suarez-Massa D, Postigo C, San Segundo D, Lopez-Hoyos M, Ortiz-Romero PL, Piris MA, Sanchez-Beato M (2014) PLCG1 mutations in cutaneous T-cell lymphomas. Blood 123:2034–2043PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G (2014) A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 46:844–849PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, Gazzola A, Gloghini A, Righi S, Rossi M, Tagliafico E, Zinzani PL, Zupo S, Baccarani M, Pileri SA (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Can Res 67:10703–10710CrossRefGoogle Scholar
  48. 48.
    Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legres L, Meignin V, Oksenhendler E, Maignin CL, Calvo F, Briere J, Gisselbrecht C, Janin A (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest J Tech Methods Pathol 84:1512–1519CrossRefGoogle Scholar
  49. 49.
    Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, Suzuki K, Sawabe M, Ohta M, Miyakoshi S, Crawley JT, Kitagawa M (2009) Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol 144:696–704PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM (2014) Lymphoma Leukemia molecular profiling P, the international peripheral TcLP. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Rho R, Laddis T, McQuain C, Selves J, Woda B, Knecht H (1996) Miliary tuberculosis in a patient with Epstein-Barr virus-associated angioimmunoblastic lymphadenopathy. Ann Hematol 72:333–335PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Konig M, Grunder K, Nilles M, Schill WB (1991) Cutaneous cryptococcosis as the first symptom of a disseminated cryptococcosis in a patient with lymphogranulomatosis X. Mycoses 34:309–311PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Luppi M, Torelli G (1996) The new lymphotropic herpesviruses (HHV-6, HHV-7, HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview. Haematologica 81:265–281PubMedPubMedCentralGoogle Scholar
  54. 54.
    Helm TN, Steck WD, Proffitt MR, Bergfeld WF, Tubbs RR, Lo J (1990) Kaposi’s sarcoma, angioimmunoblastic lymphadenopathy, and antibody to HIV-1 p24 antigen in a patient nonreactive for HIV-1 with use of ELISA. J Am Acad Dermatol 23:317–318PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Anagnostopoulos I, Hummel M, Finn T, Tiemann M, Korbjuhn P, Dimmler C, Gatter K, Dallenbach F, Parwaresch MR, Stein H (1992) Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80:1804–1812PubMedPubMedCentralGoogle Scholar
  56. 56.
    Brauninger A, Spieker T, Willenbrock K, Gaulard P, Wacker HH, Rajewsky K, Hansmann ML, Kuppers R (2001) Survival and clonal expansion of mutating “forbidden” (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma. J Exp Med 194:927–940PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, Hamoudi RA, Munson P, Bacon CM, Dogan A, Du MQ (2007) Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 138:44–53PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Dogan A, Attygalle AD, Kyriakou C (2003) Angioimmunoblastic T-cell lymphoma. Br J Haematol 121:681–691PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Attygalle AD, Kyriakou C, Dupuis J, Grogg KL, Diss TC, Wotherspoon AC, Chuang SS, Cabecadas J, Isaacson PG, Du MQ, Gaulard P, Dogan A (2007) Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 31:1077–1088PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Balague O, Martinez A, Colomo L, Rosello E, Garcia A, Martinez-Bernal M, Palacin A, Fu K, Weisenburger D, Colomer D, Burke JS, Warnke RA, Campo E (2007) Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. Am J Surg Pathol 31:1310–1322PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Dogan A, Gaulard P, Jaffe ES, Ralfkiaer E, Müller-Hermelink HK (2008) Angioimmunoblastic T-cell Lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 309–311Google Scholar
  62. 62.
    Dorfman DM, Shahsafaei A (2011) CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 35:76–83PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, Dogan A (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627–633PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, Zinzani PL, Pileri SA (2013) CD30 expression in peripheral T-cell lymphomas. Haematologica 98:e81–2PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Stacchini A, Demurtas A, Aliberti S, Francia di Celle P, Godio L, Palestro G, Novero D (2007) The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am J Clin Pathol 128:854–864PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Serke S, van Lessen A, Hummel M, Szczepek A, Huhn D, Stein H (2000) Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. Cytometry 42:180–187PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Schlegelberger B, Zhang Y, Weber-Matthiesen K, Grote W (1994) Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics. Blood 84:2640–2648PubMedPubMedCentralGoogle Scholar
  68. 68.
    Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC (2007) Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer 46:37–44PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Ruiz SJ, Cotta CV (2015) Follicular helper T-cell lymphoma: a B-cell-rich variant of T-cell lymphoma. Annals Diag Pathol 19:187–192CrossRefGoogle Scholar
  70. 70.
    Hu S, Young KH, Konoplev SN, Medeiros LJ (2012) Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol 43:1789–1798PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, Delfau-Larue MH, Marafioti T, Chott A, Gaulard P (2009) Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 33:682–690PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Moskowitz AJ, Lunning MA, Horwitz SM (2014) How I treat the peripheral T-cell lymphomas. Blood 123:2636–2644PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Muller-Hermelink HK, Wilhelm M (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-Cell Lymphomas: results of a prospective multicenter study. J Clin Oncol Official J Am Soc Clin Oncol 27:106–113CrossRefGoogle Scholar
  74. 74.
    Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010;151:159-66PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    International T-Cell Lymphoma Project (2008) International peripheral T-Cell and natural killer/T-Cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130CrossRefGoogle Scholar
  76. 76.
    Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM (2004) Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467–1475PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma study group. Blood 116:3418–3425PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Ellin F, Landstrom J, Jerkeman M, Relander T (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma registry. Blood 124:1570–1577PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Osterborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Ostenstad B, Fagerli UM, Gadeberg OV, Sundstrom C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol Official J Am Soc Clin Oncol 30:3093–3099CrossRefGoogle Scholar
  80. 80.
    Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, Zelenetz A, Matasar MJ, Sauter C, Goldberg J, Horwitz SM (2013) A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk 13:664–670PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Mehta-Shah N, Ito K, Bantilan KS, Moskowitz AJ, Sauter CS, Horwitz SM, Schoder H (2016) Interim PET evaluation by deauville criteria is an effective risk stratification tool in PTCL. Blood 128:186Google Scholar
  82. 82.
    Lunning MA, Moskowitz AJ, Horwitz S (2013) Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve. J Clin Oncol 31:1922–1927PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M (2008) Societe Francaise de Greffe de Moelle et de Therapie C. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264–2271PubMedCrossRefGoogle Scholar
  84. 84.
    Mehta-Shah N, Lunning MA, Ruan J, Nair S, Boruchov AM, Moskowitz AJ, Gerecitano JF, Hamlin PA, Leonard JP, Lynch P, Matasar MJ, Moskowitz C, Portlock C, Younes A, Myskowski P, Nolan P, Palomba ML, Vredenburgh J, Querfeld C, Straus DJ, Zelenetz A, Schroder H, Rademaker J, Schaffer W, Horwitz SM (2015) A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma. Hematol Oncol 33 (Supplement 1)Google Scholar
  85. 85.
    Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH (2011) A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 22:1608–1613PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW (2007) Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transp 40:239–243CrossRefGoogle Scholar
  87. 87.
    Horwitz SMC, Kewalramani T, Hamlin P, Straus D, O’Connor O, Noy A, Portlock C, Nimer S, Palomba L, Zelenetz A (2005) Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat. Blood (ASH Annual Meeting Abstracts) 106, abstract 2679Google Scholar
  88. 88.
    Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN (2013) Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma. J Clin Oncol Official J Am Soc Clin Oncol 31:3100–3109CrossRefGoogle Scholar
  89. 89.
    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30:631–636PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A (2015) Belinostat in patients with relapsed or refractory peripheral T-Cell Lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492–2499PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182–1189PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Amorim S, Ribrag V, Coiffier B (2014) Final Analysis of the RO-CHOP Phase Ib/II Study: romidepsin in association with CHOP in patients with peripheral T-Cell Lymphoma (PTCL). Blood (ASH Annual Meeting Abstracts) 124:504Google Scholar
  93. 93.
    Mehta-Shah N, Moskowitz AJ, Lunning M, Lynch P, Scheuerman M, Kumar A, Gerecitano JF, Zelenetz AD, Hamlin PA, Noy A, Matasar MJ, Palomba ML, Younes A, Schaffer W, Grewal R, Rademaker J, Sauter CS, Dahi PB, Myskowski P, Kheterpal M, Dogan A, Pulitzer M, Tang L, Ni A, Horwitz SM (2016) A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-Cell lymphomas. Blood (ASH Annual Meeting Abstracts) 128:2991Google Scholar
  94. 94.
    Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, Siddiqi T, Kennedy DA, Oki Y (2014) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095–3100PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol 32:3137–3143PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Delarue R, Dupuis J, Sujobert P, Barbieux S, Marçais A, Tournilhac O, Lachenal F, Cheminant M, Sarkozy C, Fataccioli V, Morschhauser F, Hermine O, Haioun C, Gaulard P, Lemonnier F (2016) Treatment with hypomethylating agent 5-Azacytidine induces sustained response in angioimmunoblastic T Cell lymphomas. Blood (ASH Annual Meeting Abstracts) 128:4164Google Scholar
  97. 97.
    Horwitz S, O’Connor O, Jurczak W, Van Hoof A, Hess G, Gasztonyi Z, Doorduijn J, Walewski J, Brown P, Vranovsky A, Sissolak G, Aurer I, Nacinovic A, Shustov A, Chawla S, Knoblauch P, Wulf G, Visser O, Zinzani P, Masszi T (2013) Belinostat in relapsed or refractory peripheral T-cell lymphoma subtype angioimmunoblastic T-cell lymphoma: results from the pivotal BELIEF trial. Hematol Oncol 31(Suppl. 1):147Google Scholar
  98. 98.
    Delarue R, Dupuis J, Sujobert P, Barbieux S, Marçais A, Tournilhac O, Lachenal F, Cheminant M, Sarkozy C, Fataccioli V, Morschhauser F, Hermine O, Haioun C, Gaulard P, Lemonnier F (2016) Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomasGoogle Scholar
  99. 99.
    Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Bene MC, Martin A, Lamy T (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol Official J Am Soc Clin Oncol 31:104–110CrossRefGoogle Scholar
  100. 100.
    Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21:860–863PubMedCrossRefGoogle Scholar
  101. 101.
    Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116:4541–4548PubMedCrossRefGoogle Scholar
  102. 102.
    Advani R, Horwitz S, Zelenetz A, Horning SJ (2007) Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leukemia Lymp 48:521–525CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mariko Yabe
    • 1
  • Ahmet Dogan
    • 1
  • Steven M. Horwitz
    • 2
  • Alison J. Moskowitz
    • 2
    Email author
  1. 1.Hematopathology ServiceMemorial Sloan Kettering Cancer CenterNew York CityUSA
  2. 2.Lymphoma ServiceMemorial Sloan Kettering Cancer CenterNew York CityUSA

Personalised recommendations